🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 33 of 173

  1. US 11236044

    Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11236301

    Thin film cell encapsulation devices

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11230535

    CFTR regulators and methods of use thereof

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11230569

    Antiplasmodial compounds

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11230565

    Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11229609

    Compositions and methods for organ specific delivery of nucleic acids

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11229599

    Implant compositions for the unidirectional delivery of therapeutic compounds to the brain

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11229681

    Dominant-negative FGF2 antagonists

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11230568

    Melanocortin 1 receptor ligands and methods of use

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11230591

    CMV neutralizing antigen binding proteins

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11224577

    Treating infection by a platelet-targeting microbe using nanoparticles

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11225525

    Antibodies for botulinum neurotoxins

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11225514

    Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11224645

    Glycoconjugate vaccine for leishmaniasis

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11224646

    Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11224647

    Safe potent single platform vaccine against Tier 1 select agents and other pathogens

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11224655

    Targeting microbubbles

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11224624

    Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11224584

    Sleep apnea treatment

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11224656

    Scintillator nanocrystal-containing compositions and methods for their use

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11219643

    Compositions for cellular restoration and methods of making and using same

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11219697

    Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11219633

    Nucleobase analogue derivatives and their applications

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11220477

    Modulators of the eIF2alpha pathway

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11219673

    Compositions and methods for delivery of biomacromolecule agents

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11219552

    Intraocular filter device and methods of using same

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11220479

    Glucosylceramide synthase inhibitors and therapeutic methods using the same

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11219692

    Porphyrin modified telodendrimers

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11214567

    Small molecule inhibitors of MYC and uses thereof

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11213514

    Alpha-1-adrenergic receptor agonist therapy

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11213582

    Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11214595

    BK channel-modulating peptides and their use

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11213513

    Compositions and methods for promoting hair growth with Mpc1 inhibitors

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11213592

    Antibody-sting agonist conjugates and their use in immunotherapy

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11214603

    C3D cellular and acellular vaccines for the prevention and treatment of cancer

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11215617

    Treatment of metastatic prostate cancer

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11213497

    Antibiofilm formulations

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11208397

    Small molecule antagonists of sumo related modification of CRMP2 and uses thereof

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11208634

    Deimmunized therapeutic compositions and methods

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11208411

    Compositions and methods for treating parasitic diseases

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11207329

    Methods for treating GI syndrome and graft versus host disease

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11208479

    CX43 hemichannel antibodies and methods of use

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11207322

    Method and composition related to combination therapy for addiction

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11207333

    Compositions comprising triterpenoids and uses thereof for treating optic neuropathy

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11207211

    Lacrimal drug delivery device

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11207396

    Immunization to protect against adverse cardiac events relating to pneumococcal infection

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11208640

    Modulating human Cas9-specific host immune response

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11207429

    Method and compositions for orally administered contrast agents for MR imaging

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.